Accessibility Menu
Marker Therapeutics logo

Marker Therapeutics(NASDAQ) MRKR

Current Price$1.29
Market Cap$21.34MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2002)-100%
5 Year-95%
1 Year-25%
1 Month-4%
Marker Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 1.282026-07-20
Marker Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-12.33%USD 1.462026-07-13
1 month-3.76%USD 1.332026-06-18
3 month-17.95%USD 1.562026-04-21
Year to date-14.09%USD 1.492025-12-31
1 year-24.71%USD 1.702025-07-18
3 year-80.64%USD 6.612023-07-21
5 year-94.58%USD 23.602021-07-21
Since inception-100%USD 1,785,017.852002-07-16

Marker Therapeutics Financials at a Glance

Market Cap

$21.34MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$2.09M

Net Income (TTM)

-$10.90M

EPS (TTM)

-$0.67

P/E Ratio

-1.90

Dividend

$0.00

Beta (Volatility)

1.06 (Average)

Price

$1.29

Volume

6,332.274

Open

$1.28

Previous Close

$1.28

Daily Range

$1.28 - $1.32

52-Week Range

$0.81 - $2.46

Estimated Earnings Date

Aug 13, 2026

MRKR News

biotech down

Here's Why Marker Therapeutics Fell as Much as 11.5% Today

Maxx ChatskoApr 17, 2019

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Marker Therapeutics

Marker Therapeutics develops cell therapies and vaccines for cancer patients. Its treatments aim to help people with blood cancers and solid tumors. The company’s products use the body’s own immune cells to target cancer.

What’s in the Marker Toolbox?

  • MAR-T Cell Therapies: Non-engineered immune cell treatments for blood cancers and solid tumors (100% of revenue from grants supporting these programs).
  • Autologous MAR-T (MT-601): Uses a patient’s own immune cells to treat lymphoma and pancreatic cancer.
  • Off-the-Shelf MAR-T (MT-401-OTS): Uses donor immune cells for acute myeloid leukemia and myelodysplastic syndromes.
  • Peptide-Based Vaccines (TPIV100/110, TPIV200): Vaccines in clinical trials for breast and ovarian cancers.

Growth Moves: Marker’s Expansion Playbook

  • Advanced MT-601 into Phase 1 APOLLO study for lymphoma in 2025.
  • Launched MT-401-OTS program for leukemia in October 2025.
  • Signed manufacturing deal with Cellipont Bioservices in June 2025 for clinical trial support.
  • Received over $15 million in grants from 2024 to 2025 for research.
  • Ended manufacturing agreement with Cell Ready in March 2025, incurring a $0.5 million loss.

Why Marker Stands Out (Without the Lab Coat)

Marker’s therapies use non-engineered immune cells, aiming for simpler and faster production than gene-edited treatments. The company’s process targets several cancer markers at once, which may help prevent cancer from escaping treatment. Strategic partnerships and grant funding support its research and development efforts.

Five Things You Need to Know

  • Revenue was $1 million in Q3 2025, down 36% from Q3 2024.
  • Net loss was $2 million in Q3 2025, improved 11% year-over-year.
  • Cash, cash equivalents, and restricted cash totaled $17 million at December 31, 2025.
  • Operating expenses were $16.4 million in 2025, down 7% from 2024.
  • All revenue comes from grants; no product sales as of 2025.

Bottom Line

Marker focuses on developing immune-based cancer therapies, funded mainly by grants. The company remains in early clinical stages, with ongoing research and operational challenges.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

5

CEO

Juan F. Vera, MD

Website

www.markertherapeutics.com

Headquarters

Houston, TX 77027, US

MRKR Financials

Key Financial Metrics (TTM)

Gross Margin

-347.23%

Operating Margin

-589.95%

Net Income Margin

-520.35%

Return on Equity

-73.29%

Return on Capital

-76.74%

Return on Assets

-62.50%

Earnings Yield

-52.63%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$21.34MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

16.67M

Volume

6.33K

Avg. Volume

65.69K

Financials (TTM)

Gross Profit

-$7.27M

Operating Income

-$12.35M

EBITDA

-$10.91M

Operating Cash Flow

-$7.92M

Capital Expenditure

-$6.00

Free Cash Flow

-$7.92M

Cash & ST Invst.

$14.92M

Total Debt

$0.00

Marker Therapeutics Performance Analysis

Marker Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 3,513,544183.0%
20232023-12-31USD 3,311,133-5.8%
20242024-12-31USD 6,591,08099.1%
20252025-12-31USD 3,546,669-46.2%
Marker Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30146.7%
Q32025-09-3043.2%
Q42025-12-31-100.0%
Q12026-03-31N/A
Marker Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -3.58-34.5%
20232023-12-31USD -1.93-46.3%
20242024-12-31USD -1.20-38.0%
20252025-12-31USD -0.79-33.5%
Marker Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3027.5%
Q32025-09-3058.6%
Q42025-12-3116.7%
Q12026-03-31-60.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

-100.0%

Gross Profit

-$2.84M

-2.0%

Gross Margin

0.00%

N/A

Market Cap

$21.34MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$4.27M

N/A

Employees

5

N/A

Net Income

-$3.18M

+28.5%

EBITDA

-$3.18M

N/A

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$14.92M

+8.9%

Total Debt

$0.00

N/A

Accounts Receivable

$1.38M

-44.0%

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

N/A

Return on Assets

-62.50%

N/A

Return on Invested Capital

-89.55%

N/A

Free Cash Flow

-$1.40M

+74.5%

Operating Cash Flow

-$1.40M

+74.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
SNSESensei Biotherapeutics, Inc.
$13.85-22.28%
PHIOPhio Pharmaceuticals Corp.
$1.13+4.17%
COCPCocrystal Pharma, Inc.
$0.94+1.34%
CLRBCellectar Biosciences, Inc.
$2.63+4.27%

Trending Stocks

Symbol / CompanyPricePrice Chg
VIVKVivakor
$5.49+2.17%
UTZUtz Brands
$14.12+0.89%
AALAmerican Airlines Group
$15.28+0.01%
SOFISoFi Technologies
$17.44+0.02%

Questions About MRKR

What is the current price of Marker Therapeutics?

Marker Therapeutics is trading at $1.32 per share.

What is the 52-week range for Marker Therapeutics?

Over the past 52 weeks, Marker Therapeutics has traded between $0.81 and $2.46.

How much debt does Marker Therapeutics have?

As of the most recent reporting period, Marker Therapeutics reported total debt of $0.00.

How much cash does Marker Therapeutics have on hand?

Marker Therapeutics reported $15.64M in cash and cash equivalents in its most recent financial results.

What is Marker Therapeutics’s dividend yield?

Marker Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services